Antimicrobial susceptibilities of Brucella isolates from various clinical speciemens

International Journal of Medical Sciences

Volumn 8, Issue 3, 2011, Pages 198-202

  Bayram, Yasemin ^a   Korkoca, Hanifi ^b   Aypak, Cenk ^c   Parlak, Mehmet ^d   Cikman, Aytekin ^d   Kilic, Selcuk ^e   Berktas, Mustafa ^d  

^a Van Education and Research Hospital   (Turkey)

^b MU ALPARSLAN UNIVERSITY   (Turkey)

^c Gevas Hospital   (Turkey)

^d YUZUNCU YIL UNIVERSITY   (Turkey)

^e Refik Saydam Hygiene Center   (Turkey)

Author keywords

Antimicrobial susceptibility; Brucella; E test; Tigecycline

Indexed keywords

COTRIMOXAZOLE; DOXYCYCLINE; RIFAMPICIN; STREPTOMYCIN; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BRUCELLA; BRUCELLA MELITENSIS; BRUCELLOSIS; CONTROLLED STUDY; EPSILOMETER TEST; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TURKEY (REPUBLIC);

EID: 79955508912     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8.198     Document Type: Article

References (37)

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006; 6:91-99.
2. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 6th ed. Phil-adelphia: Churchill Livingstone; 2005: 2669-2672.
3. Black TF. Brucellosis. In: Cohen J, Powderly WG, eds. Infectious diseases; 2nd ed. St Louis: Mosby; 2004: 1665-1667.
4. Doǧanay M, Meşe-Alp E. In: Topçu AW, Söyletir G, Doganay M, eds. Infeksiyon hastalklar ve mikrobiyolojisi; 3rd ed. Is-tanbul: Nobel Tp Kitabevleri; 2008: 897-909.
5. Yüce A, Alp-Çavuş S. Türkiye'de bruselloz: genel bakş. Klimik derg 2006; 19:87-97.
6. Ceylan E, Irmak H, Buzgan T, Karahocagil MK, Evirgen Ö, Sakarya N, et al. Van iline baǧl baz köylerde insan ve hayvan populasyonunda bruselloz seroprevalans. Van Tp Derg. 2003; 10:1-5.
7. Joint Food and Agriculture Organization/World Health Organization. FAO-WHO Expert Committee on Brucellosis (sixth report). WHO Technical Report Series No. 740. Geneva: World Health Organisation; 1986: 56-57.
8. Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Doku-zoguz B. In vitro antimicrobial susceptibility of Brucella species. Intern J Antimicrob Agents. 2004; 23:405-407.
9. Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, Orrantia-Gradin R, Hernandez-Oliva GM, Guttierrez-Rubio AT, Cardenosa O. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis. 2004; 36:636-638
10. Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A, Erbay A. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis. 2003; 35(5):337-338.
11. Köse S, Kiliç S, Ozbel Y. Identification of Brucella species iso-lated from proven brucellosis patients in Izmir, Turkey. J Basic Microbiol. 2005; 45(4):323-327.
12. Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis. 2007; 39(5):432-434.
13. Kilic S, Dizbay M, Cabadak H. In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis. J Chemother. 2008; Feb;20(1):33-37.
14. Garcia-Rodriguez JA, Garcia-Sanchez JE, Trujillano I. Lack of effective bactericidal activity of new quinolones against Bru-cella spp. Antimicrob Agents Chemother. 1991; 35:756-759.
15. Qadri SM, Halim MA, Ueno Y, Abumustafa FM, Postle AG. Antibacterial activity of azithromycin against Brucella melitensis. Chemotherapy. 1995;41(4):253-256.
16. Kilic S, Dizbay M, Hizel K, Arman D. In vitro synergistic activ-ity of antibiotic combinations against Brucella melitensis using E-test methodology. Braz J Mic. 2008; 39:1-7.
17. Grignon B, Grollier G, Coindreau MF, Becq-Giraudon B. Rifampicin resistance in a strain of Brucella melitensis after treatment with doxycycline and rifampicin. J Antimicrob Chemother. 1986; 18:648-649.
18. Kinsara A, Al-Mowallad A, Osoba O A. Increasing resistance of Brucellae to co-trimoxazole. Antimicrob. Agents Chemother. 1999; 43:1531.
19. Alton GG, Jones LM, Angus RD, Verger JM. Techniques for the brucellosis Laboratory. Paris: Institut National de la recherche Agronomique (INRA). 1988; 34-61.
20. Shapiro SD, Wong JD. Brucella. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manuel of clinical microbi-ology, vol 1, 7th ed. Washington DC: ASM Press; 1999: 625-631.
21. King A. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J Antimicrob Chemother. 2001; 48 (Suppl S1): S77-S80.
22. Yamazhan T, Aydemir Ş, Tünger A, Serter D, Gökengin D. In vitro activities of various antimicrobials against Brucella melitensis strains in the Agean Region in Turkey. Med Princ Pract. 2005; 14: 413-416.
23. Ayaşlioǧlu E, Kiliç S, Aydin K, Kiliç D, Kaygusuz S, Aǧalar C. Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. Turk J Med Sci. 2008; 38(3): 257-262.
24. Turkmani A, Ionnidis A, Christidou A, Psaroulaki A, Loukai-des F, Tselentis Y. In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicr. 2006; 5: 24.
25. Marianelli C, Graziani C, Santangelo C, Xibilia MiT, Imbriani A, Amato R, Neri D, Cuccia M, Rinnone S, Di Marco V, Ciuchini F. Molecular epidemiological and antibiotic susceptibility char-acterization of Brucella isolates from humans in Sicily, Italy. J Clin Microbiol. 2007; 45(9): 2923-2928.
26. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Sixteenth in-formational supplement; CLSI document M 100-S16. Wayne, PA, USA: CLSI. 2006.
27. Gür D, Kocagöz S, Akova M, Ünal S. Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicr Agents Chemother. 1999; 43(9): 2337.
28. Madkour MM. Treatment. In: Madkour MM, ed. Madkour's Brucellosis. 2nd ed. Berlin Heidelberg New York: Spring-er-Verlag; 2001: 241-261.
29. Rubinstein ER, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G, Anderson M, Harrison K. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother. 1991; 35:1925-1927.
30. Akova M, Gur D, Livermore DM, Kocagoz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother. 1999; 43: 1298-1300.
31. Memish Z, Mah MW, Al Mahmoud S, Al Shaalan M, Khan MY. Brucella bacteraemia: clinical and laboratory observations in 160 patients. J Infect. 2000; 40(1):59-63.
32. Marianelli C, Ciuchini F, Tarantino M, Pasquali P, Adone R. Genetic bases of the rifampin resistance phenotype in Brucella spp. J Clin Microbiol. 2004; 42:5439-5443.
33. Kocabas A, Akciger T. In: Topçu AW, Söyletir G, Doganay M, eds. Infeksiyon Hastalklar ve Mikrobiyolojisi. Istanbul: Nobel Tp Kitabevleri, 2002: 38-591.
34. Kinsara A, Al-Mowallad A, Osoba AO. Increasing resistance of Brucella to Co- Trimoxazole. Antimicrob Agents Chemother. 1999; 6: 1531.
35. Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ. Tigecy-cline: a novel glycylcycline antibiotic. Expert Rev. Anti-Infect Ther. 2006; 4:9-25
36. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother. 2005; 56: 611-614.
37. Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents. 2008; 26: 101-105.